HIV/AIDS Vaccines: A Need for New Concepts?

REFERENCES

• Sekaly R. P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?. J. Exp. Med 2008; 205: 7–12
   PubMed Web of Science ®Google Scholar
• Lu S. Human versus HIV: Round 2 defeat in AIDS vaccine development. Expert Rev. Vaccines 2008; 7: 151–153
   PubMed Web of Science ®Google Scholar
• Cohen J. Public health. AIDS vaccine trial produces disappointment and confusion. Science 2003; 299: 1290–1291
   PubMed Web of Science ®Google Scholar
• Gilbert P. B., Peterson M. L., Follmann D., Hudgens M. G., Francis D. P., Gurwith M., Heyward W. L., Jobes D. V., Popovic V., Self S. G., Sinangil F., Burke D., Berman P. W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis 2005; 191: 666–677
   PubMed Web of Science ®Google Scholar
• Fauci A. S., Johnston M. I., Dieffenbach C. W., Burton D. R., Hoxie J. A., Martin M., Overbaugh J., Watkins D. I., Mahmoud A., Greene W. HIV vaccine research: The way forward. Science 2008; 321: 530–532
   PubMed Web of Science ®Google Scholar
• von A. Bubnoff. Clues from CROI. IAVI Report 2008; 12(1)1–5
   Google Scholar
• Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M., et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355: 728–730
   PubMed Web of Science ®Google Scholar
• Parren P. W., Marx P. A., Hessell A. J., Luckay A., Harouse J., Cheng-Mayer C., Moore J. P., Burton D. R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol 2001; 75: 8340–8347
   PubMed Web of Science ®Google Scholar
• Xu W., Hofmann-Lehmann R., McClure H. M., Ruprecht R. M. Passive immunization with human neutralizing monoclonal antibodies: Correlates of protective immunity against HIV. Vaccine 2002; 20: 1956–1960
   Google Scholar
• LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249: 932–935
   PubMed Web of Science ®Google Scholar
• Moore J. P., Nara P. L. The role of the V3 loop of gp120 in HIV infection. AIDS 1991; 5(Suppl 2)S21–33
   Google Scholar
• Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990; 345: 622–625
   PubMed Web of Science ®Google Scholar
• Bruck C., Thiriart C., Fabry L., Francotte M., Pala P., Van Opstal O., Culp J., Rosenberg M., De Wilde M., Heidt P., Heeney J. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994; 12: 1141–1148
   Google Scholar
• Girard M., Meignier B., Barre-Sinoussi F., Kieny M. P., Matthews T., Muchmore E., Nara P. L., Wei Q., Rimsky L., Weinhold K., et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol 1995; 69: 6239–6248
   Google Scholar
• Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F., 3rd, Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol 1995; 69: 101–19
   PubMed Web of Science ®Google Scholar
• Pantophlet R., Burton D. R. GP120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol 2006; 24: 739–769
   PubMed Web of Science ®Google Scholar
• Dey B., Del Castillo C. S., Berger E. A. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol 2003; 77: 2859–2865
   PubMed Web of Science ®Google Scholar
• Kwong P. D., Doyle M. L., Casper D. J., Cicala C., Leavitt S. A., Majeed S., Steenbeke T. D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P. W., Robinson J., Van Ryk D., Wang L., Burton D. R., Freire E., Wyatt R., Sodroski J., Hendrickson W. A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420: 678–682
   PubMed Web of Science ®Google Scholar
• Wei X., Decker J. M., Wang S., Hui H., Kappes J. C., Wu X., Salazar-Gonzalez J. F., Salazar M. G., Kilby J. M., Saag M. S., Komarova N. L., Nowak M. A., Hahn B. H., Kwong P. D., Shaw G. M. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307–312
   PubMed Web of Science ®Google Scholar
• Mascola J. R., Snyder S. W., Weislow O. S., Belay S. M., Belshe R. B., Schwartz D. H., Clements M. L., Dolin R., Graham B. S., Gorse G. J., Keefer M. C., McElrath M. J., Walker M. C., Wagner K. F., McNeil J. G., McCutchan F. E., Burke D. S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis 1996; 173: 340–348
   PubMed Web of Science ®Google Scholar
• Richman D. D., Wrin T., Little S. J., Petropoulos C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2003; 100: 4144–4149
   PubMed Web of Science ®Google Scholar
• Burton D. R., Desrosiers R. C., Doms R. W., Koff W. C., Kwong P. D., Moore J. P., Nabel G. J., Sodroski J., Wilson I. A., Wyatt R. T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol 2004; 5: 233–236
   PubMed Web of Science ®Google Scholar
• Phogat S., Wyatt R. T., Karlsson G. B. Hedestam, Inhibition of HIV-1 entry by antibodies: Potential viral and cellular targets. J. Intern. Med 2007; 262: 26–43
   PubMed Web of Science ®Google Scholar
• Koch M., Pancera M., Kwong P. D., Kolchinsky P., Grundner C., Wang L., Hendrickson W. A., Sodroski J., Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003; 313: 387–400
   PubMedGoogle Scholar
• Li Y., Cleveland B., Klots I., Travis B., Richardson B. A., Anderson D., Montefiori D., Polacino P., Hu S. L. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol 2008; 82: 638–651
   PubMedGoogle Scholar
• Barnett S. W., Srivastava I. K., Kan E., Zhou F., Goodsell A., Cristillo A. D., Ferrai M. G., Weiss D. E., Letvin N. L., Montefiori D., Pal R., Vajdy M. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008; 22: 339–348
   PubMed Web of Science ®Google Scholar
• Dey B., Pancera M., Svehla K., Shu Y., Xiang S. H., Vainshtein J., Li Y., Sodroski J., Kwong P. D., Mascola J. R., Wyatt R. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: Antigenicity, biophysics, and immunogenicity. J. Virol 2007; 81: 5579–5593
   PubMed Web of Science ®Google Scholar
• Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C. V., Kalyanaraman V. S., DeVico A., Pal R. Crosslinked HIV-1 envelope CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. USA 2002; 99: 11842–11847
   PubMed Web of Science ®Google Scholar
• Wang S., Pal R., Mascola J. R., Chou T. H., Mboudjeka I., Shen S., Liu Q., Whitney S., Keen T., Nair B. C., Kalyanaraman V. S., Markham P., Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D, and E. Virology 2006; 350: 34–47
   PubMed Web of Science ®Google Scholar
• Wang S., Kennedy J. S., West K., Montefiori D. C., Coley S., Lawrence J., Shen S., Green S., Rothman A. L., Ennis F. A., Arthos J., Pal R., Markham P., Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26: 1098–1110
   PubMedGoogle Scholar
• Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol 1994; 68: 4650–4655
   PubMed Web of Science ®Google Scholar
• Kuroda M. J., Schmitz J. E., Charini W. A., Nickerson C. E., Lifton M. A., Lord C. I., Forman M. A., Letvin N. L. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol 1999; 162: 5127–5233
   PubMed Web of Science ®Google Scholar
• Musey L., Hughes J., Schacker T., Shea T., Corey L., McElrath M. J. Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med 1997; 337: 1267–1274
   PubMed Web of Science ®Google Scholar
• Ogg G. S., Jin X., Bonhoeffer S., Dunbar P. R., Nowak M. A., Monard S., Segal J. P., Cao Y., Rowland-Jones S. L., Cerundolo V., Hurley A., Markowitz M., Ho D. D., Nixon D. F., McMichael A. J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279: 2103–2106
   PubMed Web of Science ®Google Scholar
• Betts M. R., Krowka J. F., Kepler T. B., Davidian M., Christopherson C., Kwok S., Louie L., Eron J., Sheppard H., Frelinger J. A. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res. Hum. Retroviruses 1999; 15: 1219–1228
   Google Scholar
• Critchfield J. W., Lemongello D., Walker D. H., Garcia J. C., Asmuth D. M., Pollard R. B., Shacklett B. L. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J. Virol 2007; 81: 5460–5471
   PubMedGoogle Scholar
• Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barre-Sinoussi F., Delfraissy J. F., Sinet M., Pancino G., Venet A. HIV controllers exhibit potent CD8 T-cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 2007; 104: 6776–6781
   PubMed Web of Science ®Google Scholar
• Betts M. R., Nason M. C., West S. M., De Rosa S. C., Migueles S. A., Abraham J., Lederman M. M., Benito J. M., Goepfert P. A., Connors M., Roederer M., Koup R. A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006; 107: 4781–4789
   PubMed Web of Science ®Google Scholar
• Turnbull E. L., Lopes A. R., Jones N. A., Cornforth D., Newton P., Aldam D., Pellegrino P., Turner J., Williams I., Wilson C. M., Goepfert P. A., Maini M. K., Borrow P. HIV-1 epitope-specific CD8+ T-cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J. Immunol 2006; 176: 6130–6146
   Google Scholar
• Almeida J. R., Price D. A., Papagno L., Arkoub Z. A., Sauce D., Bornstein E., Asher T. E., Samri A., Schnuriger A., Theodorou I., Costagliola D., Rouzioux C., Agut H., Marcelin A. G., Douek D., Autran B., Appay V. Superior control of HIV-1 replication by CD8+ T-cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med 2007; 204: 2473–2485
   PubMed Web of Science ®Google Scholar
• Schmitz J. E., Kuroda M. J., Santra S., Sasseville V. G., Simon M. A., Lifton M. A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B. J., Ghrayeb J., Forman M. A., Montefiori D. C., Rieber E. P., Letvin N. L., Reimann K. A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857–860
   PubMed Web of Science ®Google Scholar
• Robinson H. L., Amara R. R. T-cell vaccines for microbial infections. Nat. Med 2005; 11: S25–32
   PubMed Web of Science ®Google Scholar
• McMichael A. J. HIV vaccines. Annu. Rev. Immunol 2006; 24: 227–255
   PubMed Web of Science ®Google Scholar
• MacGregor R. R., Boyer J. D., Ugen K. E., Lacy K. E., Gluckman S. J., Bagarazzi M. L., Chattergoon M. A., Baine Y., Higgins T. J., Ciccarelli R. B., Coney L. R., Ginsberg R. S., Weiner D. B. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis 1998; 178: 92–100
   PubMed Web of Science ®Google Scholar
• Giri M., Ugen K. E., Weiner D. B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin. Microbiol. Rev 2004; 17: 370–389
   PubMed Web of Science ®Google Scholar
• Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., Wolf H., Wagner R. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol 2001; 75: 10991–11001
   PubMed Web of Science ®Google Scholar
• Barouch D. H., Santra S., Schmitz J. E., Kuroda M. J., Fu T. M., Wagner W., Bilska M., Craiu A., Zheng X. X., Krivulka G. R., Beaudry K., Lifton M. A., Nickerson C. E., Trigona W. L., Punt K., Freed D. C., Guan L., Dubey S., Casimiro D., Simon A., Davies M. E., Chastain M., Strom T. B., Gelman R. S., Montefiori D. C., Lewis M. G., Emini E. A., Shiver J. W., Letvin N. L. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290: 486–492
   PubMed Web of Science ®Google Scholar
• Schadeck E. B., Sidhu M., Egan M. A., Chong S. Y., Piacente P., Masood A., Garcia-Hand D., Cappello S., Roopchand V., Megati S., Quiroz J., Boyer J. D., Felber B. K., Pavlakis G. N., Weiner D. B., Eldridge J. H., Israel Z. R. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SI Vgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006; 24: 4677–4687
   PubMed Web of Science ®Google Scholar
• Boyer J. D., Robinson T. M., Kutzler M. A., Vansant G., Hokey D. A., Kumar S., Parkinson R., Wu L., Sidhu M. K., Pavlakis G. N., Felber B. K., Brown C., Silvera P., Lewis M. G., Monforte J., Waldmann T. A., Eldridge J., Weiner D. B. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl. Acad. Sci. USA 2007; 104: 18648–18653
   PubMed Web of Science ®Google Scholar
• Otten G. R., Schaefer M., Doe B., Liu H., Megede J. Z., Donnelly J., Rabussay D., Barnett S., Ulmer J. B. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006; 24: 4503–4509
   PubMed Web of Science ®Google Scholar
• Hirao L. A., Wu L., Khan A. S., Hokey D. A., Yan J., Dai A., Betts M. R., Draghia-Akli R., Weiner D. B. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008
   Google Scholar
• Luckay A., Sidhu M. K., Kjeken R., Megati S., Chong S. Y., Roopchand V., Garcia-Hand D., Abdullah R., Braun R., Montefiori D. C., Rosati M., Felber B. K., Pavlakis G. N., Mathiesen I., Israel Z. R., Eldridge J. H., Egan M. A. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol 2007; 81: 5257–5269
   PubMed Web of Science ®Google Scholar
• Schoenly K. A., Weiner D. B. Human immunodeficiency virus type 1 vaccine development: Recent advances in the cytotoxic T-lymphocyte platform “spotty business.”. J. Virol 2008; 82: 3166–3180
   PubMedGoogle Scholar
• Ramshaw I. A., Ramsay A. J. The prime-boost strategy: Exciting prospects for improved vaccination. Immunol. Today 2000; 21: 163–165
   PubMedGoogle Scholar
• Schnell M. J. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol. Lett 2001; 200: 123–129
   PubMed Web of Science ®Google Scholar
• Barouch D. H., Pau M. G., Custers J. H., Koudstaal W., Kostense S., Havenga M. J., Truitt D. M., Sumida S. M., Kishko M. G., Arthur J. C., Korioth-Schmitz B., Newberg M. H., Gorgone D. A., Lifton M. A., Panicali D. L., Nabel G. J., Letvin N. L., Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol 2004; 172: 6290–6297
   PubMed Web of Science ®Google Scholar
• Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., Robbins P. D., Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol 2004; 11: 351–357
   PubMedGoogle Scholar
• Gaydos C. A., Gray G. C. Adenovirus vaccines. Vaccines, Fifth Edition, S. A. Plotkin, W. A. Orenstein, P. A. Offit. Saunders, Elsevier. 2008; 1103–1122
   Google Scholar
• Roberts D. M., Nanda A., Havenga M. J., Abbink P., Lynch D. M., Ewald B. A., Liu J., Thorner A. R., Swanson P. E., Gorgone D. A., Lifton M. A., Lemckert A. A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K. G., Goudsmit J., Barouch D. H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441: 239–243
   PubMed Web of Science ®Google Scholar
• Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M. P., Kostense S., Penders G., Helmus N., Koudstaal W., Cecchini M., Wetterwald A., Sprangers M., Lemckert A., Ophorst O., Koel B., van Meerendonk M., Quax P., Panitti L., Grimbergen J., Bout A., Goudsmit J., Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol 2003; 77: 8263–8171
   PubMed Web of Science ®Google Scholar
• Abbink P., Lemckert A. A., Ewald B. A., Lynch D. M., Denholtz M., Smits S., Holterman L., Damen I., Vogels R., Thorner A. R., O'Brien K. L., Carville A., Mansfield K. G., Goudsmit J., Havenga M. J., Barouch D. H. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol 2007; 81: 4654–4663
   PubMed Web of Science ®Google Scholar
• Fitzgerald J. C., Gao G. P., Reyes-Sandoval A., Pavlakis G. N., Xiang Z. Q., Wlazlo A. P., Giles-Davis W., Wilson J. M., Ertl H. C. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol 2003; 170: 1416–1422
   PubMed Web of Science ®Google Scholar
• McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M. O., Hensley S. E., Lin S. W., Li Y., Giles-Davis W., Cun A., Zhou D., Xiang Z., Letvin N. L., Ertl H. C. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol 2007; 81: 6594–6604
   PubMed Web of Science ®Google Scholar
• Tatsis N., Blejer A., Lasaro M. O., Hensley S. E., Cun A., Tesema L., Li Y., Gao G. P., Xiang Z. Q., Zhou D., Wilson J. M., Ertl H. C. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol. Ther 2007; 15: 608–617
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 2007; 318: 1048–1049
   PubMed Web of Science ®Google Scholar
• Staprans S. I., Barry A. P., Silvestri G., Safrit J. T., Kozyr N., Sumpter B., Nguyen H., McClure H., Montefiori D., Cohen J. I., Feinberg M. B. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T-cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. USA 2004; 101: 13026–13031
   PubMed Web of Science ®Google Scholar
• Richardson J., Broche S., Baud S., Leste-Lasserre T., Femenia F., Levy D., Moraillon A., Pancino G., Sonigo P. Lymphoid activation: A confounding factor in AIDS vaccine development?. J. Gen. Virol 2002; 83: 2515–2621
   Google Scholar
• Kantakamalakul W., De Souza M., Karnasuta C., Brown A., Gurunathan S., Birx D., Thongcharoen P., Taveg T. Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand. AIDS Res. Hum. Retroviruses 2004; 20: 642–644
   PubMed Web of Science ®Google Scholar
• Amara R. R., Villinger F., Altman J. D., Lydy S. L., O'Neil S. P., Staprans S. I., Montefiori D. C., Xu Y., Herndon J. G., Wyatt L. S., Candido M. A., Kozyr N. L., Earl P. L., Smith J. M., Ma H. L., Grimm B. D., Hulsey M. L., Miller J., McClure H. M., McNicholl J. M., Moss B., Robinson H. L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69–74
   PubMed Web of Science ®Google Scholar
• Smith J. M., Amara R. R., Campbell D., Xu Y., Patel M., Sharma S., Butera S. T., Ellenberger D. L., Yi H., Chennareddi L., Herndon J. G., Wyatt L. S., Montefiori D., Moss B., McClure H. M., Robinson H. L. DNA/MVA vaccine for HIV type 1: Effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res. Hum. Retroviruses 2004; 20: 1335–1347
   PubMed Web of Science ®Google Scholar
• Harari A., Bart P. A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., Burnet S., Cellerai C., Erlwein O., Barber T., Moog C., Liljestrom P., Wagner R., Wolf H., Kraehenbuhl J. P., Esteban M., Heeney J., Frachette M. J., Tartaglia J., McCormack S., Babiker A., Weber J., Pantaleo G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T-cell responses. J. Exp. Med 2008; 205: 63–77
   PubMed Web of Science ®Google Scholar
• Liu L., Chavan R., Feinberg M. B. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus ankara and play a key role in the induction of virus-specific T-cell responses in vivo. BMC Immunol 2008; 9: 15
   PubMed Web of Science ®Google Scholar
• Rayner J. O., Dryga S. A., Kamrud K. I. Alphavirus vectors and vaccination. Rev. Med. Virol 2002; 12: 279–296
   PubMed Web of Science ®Google Scholar
• Xu R., Srivastava I. K., Greer C. E., Zarkikh I., Kraft Z., Kuller L., Polo J. M., Barnett S. W., Stamatatos L. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res. Hum. Retroviruses 2006; 22: 1022–1030
   PubMedGoogle Scholar
• Pantaleo G. HIV-1 T-cell vaccines: Evaluating the next step. Lancet Infect. Dis 2008; 8: 82–83
   PubMed Web of Science ®Google Scholar
• Vogel T. U., Reynolds M. R., Fuller D. H., Vielhuber K., Shipley T., Fuller J. T., Kunstman K. J., Sutter G., Marthas M. L., Erfle V., Wolinsky S. M., Wang C., Allison D. B., Rud E. W., Wilson N., Montefiori D., Altman J. D., Watkins D. I. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol 2003; 77: 13348–13360
   PubMed Web of Science ®Google Scholar
• Casimiro D. R., Wang F., Schleif W. A., Liang X., Zhang Z. Q., Tobery T. W., Davies M. E., McDermott A. B., O'Connor D. H., Fridman A., Bagchi A., Tussey L. G., Bett A. J., Finnefrock A. C., Fu T. M., Tang A., Wilson K. A., Chen M., Perry H. C., Heidecker G. J., Freed D. C., Carella A., Punt K. S., Sykes K. J., Huang L., Ausensi V. I., Bachinsky M., Sadasivan-Nair U., Watkins D. I., Emini E. A., Shiver J. W. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J. Virol 2005; 79: 15547–15555
   PubMed Web of Science ®Google Scholar
• Mansfield K., Lang S. M., Gauduin M. C., Sanford H. B., Lifson J. D., Johnson R. P., Desrosiers R. C. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J. Virol 2008; 82: 4135–4148
   Google Scholar
• Bennett M. S., Ng H. L., Ali A., Yang O. O. Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J. Infect. Dis 2008; 197: 390–397
   PubMed Web of Science ®Google Scholar
• D'Souza M. P., Altfeld M. Measuring HIV-1-specific T cell immunity: How valid are current assays?. J. Infect. Dis 2008; 197: 337–339
   PubMed Web of Science ®Google Scholar
• Chung C., Lee W., Loffredo J. T., Burwitz B., Friedrich T. C., Giraldo Vela J. P., Napoe G., Rakasz E. G., Wilson N. A., Allison D. B., Watkins D. I. Not all cytokine-producing CD8+ T cells suppress simian immunodeficiency virus replication. J. Virol 2007; 81: 1517–1523
   Google Scholar
• Valentine L. E., Piaskowski S. M., Rakasz E. G., Henry N. L., Wilson N. A., Watkins D. I. Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J. Virol 2008; 82: 575–581
   PubMed Web of Science ®Google Scholar
• Belyakov I. M., Kuznetsov V. A., Kelsall B., Klinman D., Moniuszko M., Lemon M., Markham P. D., Pal R., Clements J. D., Lewis M. G., Strober W., Franchini G., Berzofsky J. A. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006; 107: 3258–3264
   PubMed Web of Science ®Google Scholar
• Belyakov I. M., Isakov D., Zhu Q., Dzutsev A., Berzofsky J. A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J. Immunol 2007; 178: 7211–7221
   PubMed Web of Science ®Google Scholar
• Daucher M., Price D. A., Brenchley J. M., Lamoreaux L., Metcalf J. A., Rehm C., Nies-Kraske E., Urban E., Yoder C., Rock D., Gumkowski J., Betts M. R., Dybul M. R., Douek D. C. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J. Virol 2008; 82: 4102–4114
   Google Scholar
• Vaccari M., Trindade C. J., Venzon D., Zanetti M., Franchini G. Vaccine-induced CD8+ central memory T-cells in protection from simian AIDS. J. Immunol 2005; 175: 3502–3507
   PubMed Web of Science ®Google Scholar
• Letvin N. L., Mascola J. R., Sun Y., Gorgone D. A., Buzby A. P., Xu L., Yang Z. Y., Chakrabarti B., Rao S. S., Schmitz J. E., Montefiori D. C., Barker B. R., Bookstein F. L., Nabel G. J. Preserved CD4+ central memory T-cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312: 1530–1533
   PubMed Web of Science ®Google Scholar
• Verhoeven D., Sankaran S., Silvey M., Dandekar S. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T-cells in gut mucosa but enhances their rapid restoration through central memory T-cells. J. Virol 2008; 82: 4016–4027
   Google Scholar
• Robinson H. L. HIV/AIDS vaccines: 2007. Clin. Pharmacol. Ther 2007; 82: 686–693
   PubMed Web of Science ®Google Scholar
• Pulendran B., Ahmed R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 2006; 124: 849–863
   PubMed Web of Science ®Google Scholar
• Girard M., Yue L., Barre-Sinoussi F., van der Ryst E., Meignier B., Muchmore E., Fultz P. N. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J. Virol 1996; 70: 8229–8233
   Google Scholar
• Mooij P., van der Kolk M., Bogers W. M., ten Haaft P. J., Van Der Meide P., Almond N., Stott J., Deschamps M., Labbe D., Momin P., Voss G., Von Hoegen P., Bruck C., Heeney J. L. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 1998; 12: F15–22
   PubMed Web of Science ®Google Scholar
• Stott E. J., Almond N., Kent K., Walker B., Hull R., Rose J., Silvera P., Sangster R., Corcoran T., Lines J., Silvera K., Luciw P., Murphy-Corb M., Momin P., Bruck C. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J. Gen. Virol 1998; 79: 423–432, (Pt 3)
   PubMed Web of Science ®Google Scholar
• Shiver J. W., Fu T. M., Chen L., Casimiro D. R., Davies M. E., Evans R. K., Zhang Z. Q., Simon A. J., Trigona W. L., Dubey S. A., Huang L., Harris V. A., Long R. S., Liang X., Handt L., Schleif W. A., Zhu L., Freed D. C., Persaud N. V., Guan L., Punt K. S., Tang A., Chen M., Wilson K. A., Collins K. B., Heidecker G. J., Fernandez V. R., Perry H. C., Joyce J. G., Grimm K. M., Cook J. C., Keller P. M., Kresock D. S., Mach H., Troutman R. D., Isopi L. A., Williams D. M., Xu Z., Bohannon K. E., Volkin D. B., Montefiori D. C., Miura A., Krivulka G. R., Lifton M. A., Kuroda M. J., Schmitz J. E., Letvin N. L., Caulfield M. J., Bett A. J., Youil R., Kaslow D. C., Emini E. A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331–335
   PubMed Web of Science ®Google Scholar
• McDermott A. B., O'Connor D. H., Fuenger S., Piaskowski S., Martin S., Loffredo J., Reynolds M., Reed J., Furlott J., Jacoby T., Riek C., Dodds E., Krebs K., Davies M. E., Schleif W. A., Casimiro D. R., Shiver J. W., Watkins D. I. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J. Virol 2005; 79: 15556–15566
   PubMed Web of Science ®Google Scholar
• Mattapallil J. J., Hill B., Douek D. C., Roederer M. Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge. J. Med. Primatol 2006; 35: 217–224
   PubMed Web of Science ®Google Scholar
• Suh Y. S., Park K. S., Sauermann U., Franz M., Norley S., Wilfingseder D., Stoiber H., Fagrouch Z., Heeney J., Hunsmann G., Stahl-Hennig C., Sung Y. C. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 2006; 24: 1811–1820
   PubMed Web of Science ®Google Scholar
• Koff W. C., Johnson P. R., Watkins D. I., Burton D. R., Lifson J. D., Hasenkrug K. J., McDermott A. B., Schultz A., Zamb T. J., Boyle R., Desrosiers R. C. HIV vaccine design: Insights from live attenuated SIV vaccines. Nat. Immunol 2006; 7: 19–23
   PubMed Web of Science ®Google Scholar
• Feinberg M. B., Moore J. P. AIDS vaccine models: challenging challenge viruses. Nat. Med 2002; 8: 207–210
   PubMed Web of Science ®Google Scholar
• Girard M., Bansal G., Pedroza-Martins L., Dodet B., Mehra V., Schito M., Mathieson B., Delfraissy J., Bradac J. Mucosal immunity and HIV/AIDS vaccines. Report of an international workshop, October 28–30, 2007. Vaccine 2008; 26: 3969–3977
   Google Scholar
• Watkins D. I., Burton D. R., Kallas E. G., Moore J. P., Koff W. C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med 2008; 14: 617–621
   PubMed Web of Science ®Google Scholar
• Wilson N. A., Reed J., Napoe G. S., Piaskowski S., Szymanski A., Furlott J., Gonzalez E. J., Yant L. J., Maness N. J., May G. E., Soma T., Reynolds M. R., Rakasz E., Rudersdorf R., McDermott A. B., O'Connor D. H., Friedrich T. C., Allison D. B., Patki A., Picker L. J., Burton D. R., Lin J., Huang L., Patel D., Heindecker G., Fan J., Citron M., Horton M., Wang F., Liang X., Shiver J. W., Casimiro D. R., Watkins D. I. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol 2006; 80: 5875–5885
   PubMed Web of Science ®Google Scholar
• Hel Z., Tsai W. P., Tryniszewska E., Nacsa J., Markham P. D., Lewis M. G., Pavlakis G. N., Felber B. K., Tartaglia J., Franchini G. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J. Immunol 2006; 176: 85–96
   Google Scholar
• Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., Sugimoto C., Mori K., Iida A., Hirata T., Hasegawa M., Yuasa T., Miyazawa M., Takahashi Y., Yasunami M., Kimura A., O'Connor D. H., Watkins D. I., Nagai Y. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med 2004; 199: 1709–1718
   PubMed Web of Science ®Google Scholar
• Kawada M., Igarashi H., Takeda A., Tsukamoto T., Yamamoto H., Dohki S., Takiguchi M., Matano T. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J. Virol 2006; 80: 1949–1958
   PubMed Web of Science ®Google Scholar
• Kawada M., Tsukamoto T., Yamamoto H., Takeda A., Igarashi H., Watkins D. I., Matano T. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J. Virol 2007; 81: 5202–5211
   PubMed Web of Science ®Google Scholar
• Patterson L. J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V. R., Wang L., Kalyanaraman V. S., Markham P. D., Robey F. A., Robert-Guroff M. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol 2004; 78: 2212–2221
   PubMed Web of Science ®Google Scholar
• Zhou J., Wang W., Zhong Q., Hou W., Yang Z., Xiao S. Y., Zhu R., Tang Z., Wang Y., Xian Q., Tang H., Wen L. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 2005; 23: 3202–3209
   PubMed Web of Science ®Google Scholar
• Malkevitch N. V., Patterson L. J., Aldrich M. K., Wu Y., Venzon D., Florese R. H., Kalyanaraman V. S., Pal R., Lee E. M., Zhao J., Cristillo A., Robert-Guroff M. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: Role of SIV-specific CD8+ T-cell responses. Virology 2006; 353: 83–98
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol 2007; 18: 546–556
   PubMed Web of Science ®Google Scholar
• Veazey R. S., DeMaria M., Chalifoux L. V., Shvetz D. E., Pauley D. R., Knight H. L., Rosenzweig M., Johnson R. P., Desrosiers R. C., Lackner A. A. Gastrointestinal tract as a major site of CD4+ T-cell depletion and viral replication in SIV infection. Science 1998; 280: 427–431
   PubMed Web of Science ®Google Scholar
• Brenchley J. M., Schacker T. W., Ruff L. E., Price D. A., Taylor J. H., Beilman G. J., Nguyen P. L., Khoruts A., Larson M., Haase A. T., Douek D. C. CD4+ T-cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med 2004; 200: 749–759
   PubMed Web of Science ®Google Scholar
• Mehandru S., Poles M. A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med 2004; 200: 761–770
   PubMed Web of Science ®Google Scholar
• Brenchley J. M., Price D. A., Douek D. C. HIV disease: Fallout from a mucosal catastrophe?. Nat. Immunol 2006; 7: 235–239
   PubMed Web of Science ®Google Scholar
• Mehandru S., http://www.prn.org The gastrointestinal tract in HIV-1 infection: Questions, answers, and more questions! Retrieved January 10, 2007, from Physicians' Research Network Notebook
   Google Scholar
• Bomsel M., Alfsen A. Entry of viruses through the epithelial barrier: Pathogenic trickery. Nat. Rev. Mol. Cell. Biol 2003; 4: 57–68
   PubMed Web of Science ®Google Scholar
• Shattock R. J., Haynes B. F., Pulendran B., Flores J., Esparza J. Improving defences at the portal of HIV entry: Mucosal and innate immunity. PLoS Med 2008; 5: e81
   Google Scholar
• von Bubnoff A. The great barrier. IAVI Report. 2008; 12(2)10–14
   Google Scholar
• Pope M., Haase A. T. Transmission, acute HIV-1 infection, and the quest for strategies to prevent infection. Nat. Med 2003; 9: 847–852
   PubMed Web of Science ®Google Scholar
• Haase A. T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol 2005; 5: 783–792
   PubMed Web of Science ®Google Scholar
• Li Q., Estes J. D., Duan L., Jessurun J., Pambuccian S., Forster C., Wietgrefe S., Zupancic M., Schacker T., Reilly C., Carlis J. V., Haase A. T. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J. Infect. Dis 2008; 197: 420–429
   Google Scholar
• Gori A., Tincati C., Rizzardini G., Torti C., Quirino T., Haarman M., Ben Amor K., van Schaik J., Vriesema A., Knol J., Marchetti G., Welling G., Clerici M. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J. Clin. Microbiol 2008; 46: 757–758
   PubMed Web of Science ®Google Scholar
• Boasso A., Shearer G. M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin. Immunol 2008; 126: 235–242
   PubMed Web of Science ®Google Scholar
• Silvestri G., Paiardini M., Pandrea I., Lederman M. M., Sodora D. L. Understanding the benign nature of SIV infection in natural hosts. J. Clin. Invest 2007; 117: 3148–3154
   PubMed Web of Science ®Google Scholar
• Raffatellu M., Santos R. L., Verhoeven D. E., George M. D., Wilson R. P., Winter S. E., Godinez I., Sankaran S., Paixao T. A., Gordon M. A., Kolls J. K., Dandekar S., Baumler A. J. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat. Med 2008; 14: 421–428
   PubMed Web of Science ®Google Scholar
• Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., Kimani J., Lopalco L., Piconi S., Bwayo J. J., Plummer F., Clerici M., Hinkula J. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol 2000; 165: 5170–5176
   PubMed Web of Science ®Google Scholar
• Devito C., Hinkula J., Kaul R., Lopalco L., Bwayo J. J., Plummer F., Clerici M., Broliden K. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14: 1917–1920
   PubMed Web of Science ®Google Scholar
• Belec L., Ghys P. D., Hocini H., Nkengasong J. N., Tranchot-Diallo J., Diallo M. O., Ettiegne-Traore V., Maurice C., Becquart P., Matta M., Si-Mohamed A., Chomont N., Coulibaly I. M., Wiktor S. Z., Kazatchkine M. D. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis 2001; 184: 1412–1422
   PubMed Web of Science ®Google Scholar
• Lopalco L., Barassi C., Paolucci C., Breda D., Brunelli D., Nguyen M., Nouhin J., Luong T. T., Truong L. X., Clerici M., Calori G., Lazzarin A., Pancino G., Burastero S. E. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J. Gen. Virol 2005; 86: 339–348
   PubMedGoogle Scholar
• Nguyen M., Pean P., Lopalco L., Nouhin J., Phoung V., Ly N., Vermisse P., Henin Y., Barre-Sinoussi F., Burastero S. E., Reynes J. M., Carcelain G., Pancino G. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J. Acquir. Immune Defic. Syndr 2006; 42: 412–419
   PubMedGoogle Scholar
• Alfsen A., Iniguez P., Bouguyon E., Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol 2001; 166: 6257–6265
   PubMed Web of Science ®Google Scholar
• Matoba N., Geyer B. C., Kilbourne J., Alfsen A., Bomsel M., Mor T. S. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006; 24: 5047–5055
   PubMed Web of Science ®Google Scholar
• Matoba N., Magerus A., Geyer B. C., Zhang Y., Muralidharan M., Alfsen A., Arntzen C. J., Bomsel M., Mor T. S. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc. Natl. Acad. Sci. USA 2004; 101: 13584–13589
   PubMed Web of Science ®Google Scholar
• Montero M., van Houten N. E., Wang X., Scott J. K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev 2008; 72: 54–84, table of contents
   PubMed Web of Science ®Google Scholar
• Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., Srivastava I., Bin Q., Barnett S., Donnelly J., Luciw P., Adamson L., Montefiori D., O'Hagan D. T. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 2004; 20: 1269–1281
   PubMed Web of Science ®Google Scholar
• Vajdy M., Singh M. Intranasal delivery of vaccines against HIV. Expert Opin. Drug Deliv 2006; 3: 247–259
   PubMedGoogle Scholar
• Gherardi M. M., Perez-Jimenez E., Najera J. L., Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: Enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol 2004; 172: 6209–6220
   PubMed Web of Science ®Google Scholar
• Devito C., Zuber B., Schroder U., Benthin R., Okuda K., Broliden K., Wahren B., Hinkula J. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol 2004; 173: 7078–7089
   PubMed Web of Science ®Google Scholar
• Hinkula J. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev. Vaccines 2007; 6: 203–212
   PubMed Web of Science ®Google Scholar
• Buonaguro L., Devito C., Tornesello M. L., Schroder U., Wahren B., Hinkula J., Buonaguro F. M. DNA-VLP prime-boost intranasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007; 25: 5968–5977
   PubMed Web of Science ®Google Scholar
• Johansson E. L., Wassen L., Holmgren J., Jertborn M., Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun 2001; 69: 7481–7486
   PubMed Web of Science ®Google Scholar
• Kozlowski P. A., Williams S. B., Lynch R. M., Flanigan T. P., Patterson R. R., Cu-Uvin S., Neutra M. R. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: Influence of the menstrual cycle. J. Immunol 2002; 169: 566–574
   PubMed Web of Science ®Google Scholar
• Stahl-Hennig C., Kuate S., Franz M., Suh Y. S., Stoiber H., Sauermann U., Tenner-Racz K., Norley S., Park K. S., Sung Y. C., Steinman R., Racz P., Uberla K. Atraumatic oral spray immunization with replication-deficient viral vector vaccines. J. Virol 2007; 81: 13180–13190
   Google Scholar
• Cuburu N., Kweon M. N., Song J. H., Hervouet C., Luci C., Sun J. B., Hofman P., Holmgren J., Anjuere F., Czerkinsky C. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007; 25: 8598–8610
   PubMed Web of Science ®Google Scholar
• Baltimore D. Vaccine trial provided valuable information. Nature 2008; 452: 811
   Google Scholar
• Appay V., Douek D. C., Price D. A. CD8+ T-cell efficacy in vaccination and disease. Nat. Med. 2008; 14: 623–628
   PubMed Web of Science ®Google Scholar
• Fultz P. N., Vance P. J., Endres M. J., Tao B., Dvorin J. D., Davis I. C., Lifson J. D., Montefiori D. C., Marsh M., Malim M. H., Hoxie J. A. In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J. Virol 2001; 75: 278–291
   Google Scholar
• Das A. T., Klaver B., Harwig A., Vink M., Ooms M., Centlivre M., Berkhout B. Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. J. Virol. 2007; 81: 11159–11169
   Google Scholar
• von Bubnoff A. IAVI Report 2008; 125(2)
   Google Scholar